ERTAPENEM SODIUM INJECTION

The Defense Logistics Agency awarded a delivery order under contract SPE2DX25D9900 to DMS PHARMACEUTICAL GROUP INC for the procurement of Ertapenem Sodium Injection, identified by NSN 6505015035374 and NDC codes 60505-6196-04 and 42023-0221-10, at a total price of $20.10. The award date is July 20, 2026, with delivery required by August 4, 2026 to the designated destination at Building 5505A, Wickham Avenue, Fort Campbell, KY 42223-5000. The contract is a single-line, fixed-price award with no quantity variance allowed and no options or extensions, reflecting a straightforward supply transaction under DLA’s medical procurement framework. The contractor is responsible for all delivery logistics under FOB destination terms, including shipping via traceable means exclusively—parcel post is prohibited—and must ensure each package is properly marked with the manufacturer’s CAGE code, NSN, part number, and barcoded identifiers including the NDC and internal tracking number W34MT61980035. Compliance with pharmaceutical standards is implied through adherence to FDA and DoD medical supply protocols, with inspection and acceptance occurring at the delivery point. No formal FAR clauses, MIL-STDs, or explicit quality standards such as USP are cited in the documentation, suggesting reliance on underlying master contract requirements or DLA standard operating procedures. Packaging and labeling are governed by traceability and identification mandates, but technical specifications for preservation, materials, or environmental controls are not detailed. The award notice confirms the awardee’s CAGE code 1UNB0 but provides no information on socioeconomic status, size certification, or Section K representations. Contract administration details such as payment office, COR/COTR contacts, invoicing method (e.g., WAWF), or appropriation data (AAC/TAS/ACRN) are absent; however, financial tracking codes like DIC A0A, DIST V, ADV 2A, and FC Z9 are referenced. The procurement is not associated with any solicitation evaluation factors, contract type is not explicitly defined, and no special requirements, security clearances, or OCI provisions are listed, indicating a minimal administrative footprint typical for direct medical supply acquisitions under a